121 related articles for article (PubMed ID: 36375380)
1. Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and density.
Somasundaram V; Ridnour LA; Cheng RY; Walke AJ; Kedei N; Bhattacharyya DD; Wink AL; Edmondson EF; Butcher D; Warner AC; Dorsey TH; Scheiblin DA; Heinz W; Bryant RJ; Kinders RJ; Lipkowitz S; Wong ST; Pore M; Hewitt SM; McVicar DW; Anderson SK; Chang J; Glynn SA; Ambs S; Lockett SJ; Wink DA
Redox Biol; 2022 Dec; 58():102529. PubMed ID: 36375380
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma is quintessential for NOS2 and COX2 expression in ER
Cheng RYS; Ridnour LA; Wink AL; Gonzalez AL; Femino EL; Rittscher H; Somasundaram V; Heinz WF; Coutinho L; Rangel MC; Edmondson EF; Butcher D; Kinders RJ; Li X; Wong STC; McVicar DW; Anderson SK; Pore M; Hewitt SM; Billiar TR; Glynn SA; Chang JC; Lockett SJ; Ambs S; Wink DA
Cell Death Dis; 2023 May; 14(5):319. PubMed ID: 37169743
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer.
Basudhar D; Glynn SA; Greer M; Somasundaram V; No JH; Scheiblin DA; Garrido P; Heinz WF; Ryan AE; Weiss JM; Cheng RYS; Ridnour LA; Lockett SJ; McVicar DW; Ambs S; Wink DA
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):13030-13035. PubMed ID: 29087320
[TBL] [Abstract][Full Text] [Related]
4. NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER- Breast Cancer.
Ridnour LA; Heinz WF; Cheng RY; Wink AL; Kedei N; Pore M; Imtiaz F; Femino EL; Gonzalez AL; Coutinho L; Butcher D; Edmondson EF; Rangel MC; Kinders RJ; Lipkowitz S; Wong ST; Anderson SK; McVicar DW; Li X; Glynn SA; Billiar TR; Chang JC; Hewitt SM; Ambs S; Lockett SJ; Wink DA
bioRxiv; 2023 Dec; ():. PubMed ID: 38187532
[TBL] [Abstract][Full Text] [Related]
5. Inducible nitric oxide synthase-derived extracellular nitric oxide flux regulates proinflammatory responses at the single cell level.
Somasundaram V; Gilmore AC; Basudhar D; Palmieri EM; Scheiblin DA; Heinz WF; Cheng RYS; Ridnour LA; Altan-Bonnet G; Lockett SJ; McVicar DW; Wink DA
Redox Biol; 2020 Jan; 28():101354. PubMed ID: 31683257
[TBL] [Abstract][Full Text] [Related]
6. Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients.
Ridnour LA; Cheng RYS; Heinz WF; Pore M; Gonzalez AL; Femino EL; Moffat R; Wink AL; Imtiaz F; Coutinho L; Butcher D; Edmondson EF; Rangel MC; Wong STC; Lipkowitz S; Glynn S; Vitek MP; McVicar DW; Li X; Anderson SK; Paolocci N; Hewitt SM; Ambs S; Billiar TR; Chang JC; Lockett SJ; Wink DA
bioRxiv; 2023 Dec; ():. PubMed ID: 38187660
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma is Quintessential for NOS2 and COX2 Expression in ER
Cheng RY; Ridnour LA; Wink AL; Gonzalez AL; Femino EL; Rittscher H; Somasundarum V; Heinz WF; Coutinho L; Cristina Rangel M; Edmondson EF; Butcher D; Kinders RJ; Li X; Wong STC; McVicar DW; Anderson SK; Pore M; Hewitt SM; Billiar TR; Glynn S; Chang JC; Lockett SJ; Ambs S; Wink DA
bioRxiv; 2023 Apr; ():. PubMed ID: 37066331
[TBL] [Abstract][Full Text] [Related]
8. KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8
Wu Q; Liu Z; Gao Z; Luo Y; Li F; Yang C; Wang T; Meng X; Chen H; Li J; Kong Y; Dong C; Sun S; Chen C
Theranostics; 2023; 13(4):1381-1400. PubMed ID: 36923542
[No Abstract] [Full Text] [Related]
9. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration.
Karavitis J; Hix LM; Shi YH; Schultz RF; Khazaie K; Zhang M
PLoS One; 2012; 7(9):e46342. PubMed ID: 23029485
[TBL] [Abstract][Full Text] [Related]
10. LncRNA HEIH/miR-939-5p interplay modulates triple-negative breast cancer progression through NOS2-induced nitric oxide production.
Nafea H; Youness RA; Abou-Aisha K; Gad MZ
J Cell Physiol; 2021 Jul; 236(7):5362-5372. PubMed ID: 33368266
[TBL] [Abstract][Full Text] [Related]
11. Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
Markosyan N; Chen EP; Evans RA; Ndong V; Vonderheide RH; Smyth EM
Breast Cancer Res; 2013; 15(5):R75. PubMed ID: 24004819
[TBL] [Abstract][Full Text] [Related]
12. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral Plasmid IL12 Expands CD8
Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ
Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880
[TBL] [Abstract][Full Text] [Related]
14. Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective.
Basudhar D; Bharadwaj G; Somasundaram V; Cheng RYS; Ridnour LA; Fujita M; Lockett SJ; Anderson SK; McVicar DW; Wink DA
Br J Pharmacol; 2019 Jan; 176(2):155-176. PubMed ID: 30152521
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.
Heinecke JL; Ridnour LA; Cheng RY; Switzer CH; Lizardo MM; Khanna C; Glynn SA; Hussain SP; Young HA; Ambs S; Wink DA
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6323-8. PubMed ID: 24733928
[TBL] [Abstract][Full Text] [Related]
17. SMAR1 promotes immune escape of Tri-negative Breast Cancer through a mechanism involving T-bet/PD-1 Axis.
Xiaohua W; Hongxia X; Rong D; Pingping W; Xing H; Yichao Z; Cheng C
Cell Mol Biol (Noisy-le-grand); 2018 Sep; 64(12):70-75. PubMed ID: 30301506
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors.
Baram T; Erlichman N; Dadiani M; Balint-Lahat N; Pavlovski A; Meshel T; Morzaev-Sulzbach D; Gal-Yam EN; Barshack I; Ben-Baruch A
Cells; 2021 Jun; 10(6):. PubMed ID: 34201054
[TBL] [Abstract][Full Text] [Related]
19. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
